<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004424.pub2" GROUP_ID="EPILEPSY" ID="642302081423031240" MERGED_FROM="" MODIFIED="2008-10-20 17:01:19 +0200" MODIFIED_BY="Rachael Kelly" NOTES="&lt;p&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;Exported from Review Manager 4.2&lt;br&gt;The correct author sequence is: Tremont-Lukats IW, Ratilal BO, Armstrong T, Gilbert MR.&lt;/p&gt;" NOTES_MODIFIED="2008-10-20 15:58:32 +0100" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="0058" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="12.3">
<COVER_SHEET MODIFIED="2008-10-20 17:01:19 +0200" MODIFIED_BY="Rachael Kelly">
<TITLE>Antiepileptic drugs for preventing seizures in people with brain tumors</TITLE>
<CONTACT MODIFIED="2008-10-20 17:01:19 +0200" MODIFIED_BY="Rachael Kelly"><PERSON ID="15691" ROLE="AUTHOR"><FIRST_NAME>Ivo</FIRST_NAME><MIDDLE_INITIALS>W</MIDDLE_INITIALS><LAST_NAME>Tremont-Lukats</LAST_NAME><POSITION>Clinical Assistant Professor</POSITION><EMAIL_1>itremont@earthlink.net</EMAIL_1><URL>www.culicchianeuro.com</URL><ADDRESS><DEPARTMENT>Neurology</DEPARTMENT><ORGANISATION>Louisiana State University</ORGANISATION><ADDRESS_1>1111 Medical Center Boulevard</ADDRESS_1><ADDRESS_2>Suite S-750</ADDRESS_2><CITY>Marrero</CITY><ZIP>77072</ZIP><REGION>Louisiana</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 504 349 6976</PHONE_1><FAX_1>+1 504 340 8022</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-10-20 17:01:19 +0200" MODIFIED_BY="Rachael Kelly"><PERSON ID="15691" ROLE="AUTHOR"><FIRST_NAME>Ivo</FIRST_NAME><MIDDLE_INITIALS>W</MIDDLE_INITIALS><LAST_NAME>Tremont-Lukats</LAST_NAME><POSITION>Clinical Assistant Professor</POSITION><EMAIL_1>itremont@earthlink.net</EMAIL_1><URL>www.culicchianeuro.com</URL><ADDRESS><DEPARTMENT>Neurology</DEPARTMENT><ORGANISATION>Louisiana State University</ORGANISATION><ADDRESS_1>1111 Medical Center Boulevard</ADDRESS_1><ADDRESS_2>Suite S-750</ADDRESS_2><CITY>Marrero</CITY><ZIP>77072</ZIP><REGION>Louisiana</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 504 349 6976</PHONE_1><FAX_1>+1 504 340 8022</FAX_1></ADDRESS></PERSON><PERSON ID="18174" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Bernardo</FIRST_NAME><MIDDLE_INITIALS>O</MIDDLE_INITIALS><LAST_NAME>Ratilal</LAST_NAME><SUFFIX>MD</SUFFIX><EMAIL_1>bratilal@yahoo.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurosurgery</DEPARTMENT><ORGANISATION>Hospital de São José</ORGANISATION><ADDRESS_1>Rua José António Serrano</ADDRESS_1><CITY>Lisboa</CITY><ZIP>1150-199</ZIP><COUNTRY CODE="PT">Portugal</COUNTRY><PHONE_1>+351 963047176</PHONE_1><FAX_1>+351 218841052</FAX_1></ADDRESS></PERSON><PERSON ID="13530" ROLE="AUTHOR"><PREFIX>Mrs</PREFIX><FIRST_NAME>Terri</FIRST_NAME><LAST_NAME>Armstrong</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION>Nurse Practitioner</POSITION><EMAIL_1>tsarmstr@mdanderson.org</EMAIL_1><ADDRESS><ORGANISATION>University of Texas - MD Anderson Cancer Center</ORGANISATION><ADDRESS_1>1515 Holcombe Boulevard</ADDRESS_1><ADDRESS_2>Neuro-Oncology Department, Box 431</ADDRESS_2><CITY>Houston</CITY><ZIP>77030</ZIP><REGION>Texas</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 713 792 2883</PHONE_1><FAX_1>+1 713 794 4999</FAX_1></ADDRESS></PERSON><PERSON ID="13545" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Mark</FIRST_NAME><MIDDLE_INITIALS>R</MIDDLE_INITIALS><LAST_NAME>Gilbert</LAST_NAME><SUFFIX>MD</SUFFIX><EMAIL_1>mrgilbert@mdanderson.org</EMAIL_1><ADDRESS><ORGANISATION>University of Texas - MD Anderson Cancer Center</ORGANISATION><ADDRESS_1>1515 Holcombe Boulevard</ADDRESS_1><ADDRESS_2>Neuro-oncology Department, Box 431</ADDRESS_2><CITY>Houston</CITY><REGION>77030 Texas</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 713 7922883</PHONE_1><FAX_1>+1 713 7944999</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-09-24 10:41:51 +0100" MODIFIED_BY="Rachael Kelly">
<UP_TO_DATE>
<DATE DAY="19" MONTH="2" YEAR="2008"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="19" MONTH="2" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="19" MONTH="2" YEAR="2010"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2008"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2008"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="24" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-09-24 10:43:01 +0100" MODIFIED_BY="[Empty name]"/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-10-20 15:58:32 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-09-24 10:45:23 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-09-24 10:45:05 +0100" MODIFIED_BY="[Empty name]">Antiepileptic drugs for preventing seizures in people with brain tumors</TITLE>
<SUMMARY_BODY MODIFIED="2008-09-24 10:45:23 +0100" MODIFIED_BY="[Empty name]">
<P>Up to 60% of people with brain tumors may present with seizures, or may have a seizure for the first time after diagnosis or neurosurgery. The risk of a seizure varies with the tumor type and its location in the brain. Seizures are an added burden with a negative impact on quality of life, affecting activities of daily living, independence, work, and driving. Many doctors believe that antiepileptic drugs are effective and necessary to prevent seizures (seizure prophylaxis), but this practice has been put into question. Antiepileptic drugs can have adverse effects and they interact with steroids and chemotherapy.</P>
<P>The five randomised controlled trials identified by the review authors from the medical literature looked at the antiepileptic drugs phenytoin, phenobarbital, and divalproex sodium. There was no difference between treatment with these antiepileptic drugs and placebo, or observing the patient, in preventing a first seizure in 404 people with brain tumors. The risk of an adverse event was higher for those on antiepileptic drugs (number needed to be treated to cause a harm in one person (NNH) 3). The types of adverse effects when reported in these trials were nausea, skin rash, sore gums, myelosuppression, vertigo, blurred vision, tremor, and gait unsteadiness.<BR/>The length of follow up was short in one study. No studies were identified for any of the newer antiepileptic drugs.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-09-24 10:43:57 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND>
<P>Seizures can present at any time before or after diagnosis of a brain tumor. The risk of seizures varies by tumor type and its location in the brain. For a long time we believed that preventing seizures with antiepileptic drugs (seizure prophylaxis) was effective and necessary, but the supporting evidence was little and mixed. Such evidence was the basis for previous reviews to conclude that seizure prophylaxis was ineffective in people with brain tumors.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To estimate the effectiveness of seizure prophylaxis in people with brain tumors, and to estimate the adverse event rates in the identified clinical trials.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-09-24 10:43:57 +0100" MODIFIED_BY="[Empty name]">
<P>A search strategy that included free-text and MeSH terms in LILACS, EMBASE, PubMed, CENTRAL, and <I>The Cochrane Library</I> (1966 to 2007).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Controlled clinical trials with random allocation, blinded or unblinded, and placebo or observation in the control groups.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>We screened the articles, extracted the data, and rated the validity of each trial to assess the risk of bias. Our primary outcome was the occurrence of a first seizure. The secondary outcome was adverse events. We pooled the aggregate data for each outcome into a random-effects model meta-analysis using the relative risk (RR). For adverse events, we also included the number needed to harm (NNH) using the absolute risk increase to compute the NNH.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>There was no difference between the treatment interventions and the control groups in preventing a first seizure in participants with brain tumors. The risk of an adverse event was higher for those on antiepileptic drugs than for participants not on antiepileptic drugs (NNH 3; RR 6.10, 95% CI 1.10 to 34.63; P = 0.046).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>The evidence is neutral, neither for nor against seizure prophylaxis, in people with brain tumors. These conclusions apply only for the antiepileptic drugs phenytoin, phenobarbital, and divalproex sodium. The decision to start an antiepileptic drug for seizure prophylaxis is ultimately guided by assessment of individual risk factors and careful discussion with patients.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-10-20 15:58:32 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND>
<P>Up to 60% of people with brain tumors may present with seizures or may have a seizure for the first time after diagnosis of the tumor. The risk of seizures varies according to the type of brain tumor, its grade and its location (<LINK REF="REF-Vecht-2003" TYPE="REFERENCE">Vecht 2003</LINK>; <LINK REF="REF-Vecht-2006" TYPE="REFERENCE">Vecht 2006</LINK>; <LINK REF="REF-Wen-2002" TYPE="REFERENCE">Wen 2002</LINK>). A seizure is a burden for persons with brain tumors as it has a negative impact on quality of life, including effects on activities of daily living, independence, work, and driving. Approximately 2% of people with gliomas (brain tumors of glial origin), and 3 to 16% of people with meningiomas (brain tumors arising from meningothelial cells) also seize after surgery (<LINK REF="REF-Ketz-1974" TYPE="REFERENCE">Ketz 1974</LINK>). This range of seizure probability and the additional surgical trauma has made seizure prophylaxis, that is the prevention of new onset seizures with drugs used to treat epilepsy, a widely accepted practice despite potential adverse effects and drug interactions.</P>
<P>Due to the lack of benefit from seizure prophylaxis in several retrospective studies (<LINK REF="STD-Boarini-1985" TYPE="STUDY">Boarini 1985</LINK>; <LINK REF="STD-Cohen-1988" TYPE="STUDY">Cohen 1988</LINK>; <LINK REF="STD-Mahaley-1981" TYPE="STUDY">Mahaley 1981</LINK>) and the well-known interaction of antiepileptic drugs with steroids and chemotherapy (<LINK REF="REF-Patsalos-2002" TYPE="REFERENCE">Patsalos 2002</LINK>; <LINK REF="REF-Vecht-2003" TYPE="REFERENCE">Vecht 2003</LINK>), the question of seizure prophylaxis in people with brain tumors is important. For years there has been controversy about the indications and the effectiveness of seizure prophylaxis. Some authors have recommended prophylactic antiepileptics for cerebral metastatic melanoma and also for postoperative patients with specific conditions (<LINK REF="STD-Byrne-1983" TYPE="STUDY">Byrne 1983</LINK>; <LINK REF="REF-Deutschman-1985" TYPE="REFERENCE">Deutschman 1985</LINK>) whereas others have questioned the value of such practice (<LINK REF="REF-Glantz-1997" TYPE="REFERENCE">Glantz 1997</LINK>). Most published randomized controlled trials studied this issue in persons who had brain surgery because the postoperative cerebral edema from surgical manipulation and trauma predisposed them to seizures.</P>
<P>The Quality Standards Subcommittee of the American Academy of Neurology did not recommend the routine use of prophylactic antiepileptics in people with newly diagnosed brain tumors (<LINK REF="REF-AAN-2000" TYPE="REFERENCE">AAN 2000</LINK>), based on a meta-analysis of four randomized controlled clinical trials. These guidelines have found support in the neuro-oncology community as shown in reviews since published on this topic (<LINK REF="REF-Batchelor-2006" TYPE="REFERENCE">Batchelor 2006</LINK>; <LINK REF="REF-Vecht-2003" TYPE="REFERENCE">Vecht 2003</LINK>; <LINK REF="REF-Vecht-2006" TYPE="REFERENCE">Vecht 2006</LINK>; <LINK REF="REF-Wen-2002" TYPE="REFERENCE">Wen 2002</LINK>). However, the reality is that many physicians and particularly neurosurgeons in North America and Europe still prescribe antiepileptic drugs for people with brain tumors who have not had seizures (<LINK REF="REF-Brouwers-2003" TYPE="REFERENCE">Brouwers 2003</LINK>; <LINK REF="STD-De-Santis-2002" TYPE="STUDY">De Santis 2002</LINK>; <LINK REF="REF-Hildebrand-2005" TYPE="REFERENCE">Hildebrand 2005</LINK>; <LINK REF="REF-Siomin-2005" TYPE="REFERENCE">Siomin 2005</LINK>).</P>
</BACKGROUND>
<OBJECTIVES>
<P>(1) To determine if seizure prophylaxis with antiepileptic drugs is effective in people with brain tumors.<BR/>(2) To estimate the adverse event rate from prophylactic antiepileptic drugs.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-10-20 15:58:32 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>Controlled clinical trials with random allocation, blinded or unblinded.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Participants with diagnosis of glioma, using the World Health Organization (WHO) classification of brain tumors (astrocytomas grades II, III, and IV; oligodendrogliomas grades II and III; ependymomas grades II and III); meningiomas; skull base tumors, and brain metastases from any primary tumor.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Prophylactic antiepileptics (treatment intervention) compared with no prophylaxis or prophylaxis with a placebo (control intervention). Participants may have had surgery for the diagnosis or treatment of the underlying tumor. We excluded studies comparing two anticonvulsants.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>(1) Proportion of individuals in the treatment and control groups who were free from seizures at the time defined by the trialists as time of outcome measurement. <BR/>(2) Adverse event rate: an adverse event is any untoward reaction attributed to the drug of interest regardless of dose and magnitude, causing or not causing withdrawal from the study. The drugs of interest in this review were phenytoin, carbamazepine, valproic acid, and phenobarbital. We also included in the search newer drugs such as gabapentin, pregabalin, zonisamide, lamotrigine, oxcarbazepine, levetiracetam, topiramate, vigabatrin, and tiagabine.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-10-20 15:58:32 +0100" MODIFIED_BY="[Empty name]">
<P>Our search strategy included the electronic databases CENTRAL (<I>The Cochrane Library, </I>Issue 4/2007<I>)</I>, PubMed, EMBASE, CancerLit (until October 2002), and LILACS (1966 to 2007). A list of the search terms we used is given in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>
<BR/>
</P>
<P>We also handsearched conference proceedings, textbooks, original and review articles, and contacted clinical researchers who conducted or are conducting identified trials, if necessary. We screened non-English articles, which were included if they were eligible for this review.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-09-24 10:48:12 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Application of selected criteria</B>
<BR/>Three of us (Ivo Tremont-Lukats, Bernardo Ratilal, and Terri Armstrong) independently screened all titles and abstracts identified in the literature search. We resolved any disagreement after discussion with a fourth review author (Mark Gilbert) in order to reach a consensus. We were not blinded to the author names, affiliated institutions, journal of publication, or study results. We assessed methodological quality and validity by checking: (a) randomization and description of method of concealed random allocation; (b) blinding and methods used to ensure appropriate blinding; (c) description of sample size; and (d) description of adverse events, toxicity and study withdrawals.</P>
<P>
<B>Data collection and analysis</B>
<BR/>All four of us collected data on participants, methods, interventions, outcome measurements, and adverse effects onto a spreadsheet from the original articles. We recorded outcome measurements as binary data (proportion of participants with seizures receiving or not receiving antiepileptic prophylaxis). We combined the aggregate data to obtain a pooled effect size for all included randomized trials.</P>
<P>
<B>Synthesis and presentation of data</B>
<BR/>We analyzed the collected data using the analysis module for RevMan 4.2 (<LINK REF="REF-NCC-2006" TYPE="REFERENCE">NCC 2006</LINK>). We estimated the relative risk of seizures with 95% confidence intervals (CIs) between participants receiving antiepileptic prophylaxis and individuals treated with the control intervention. We explored heterogeneity using tests for statistical heterogeneity (the Q and I<SUP>2 </SUP>statistics) and a graphical display (funnel plots). For the analysis of adverse events we used binary data to estimate the relative risk and the number needed to harm (NNH). The NNH is equal to the inverse of the absolute risk increase (ARI), which in turn is the difference between the event rate of participants treated with antiepileptics and the control event rate. There was no opportunity to run sensitivity analyses in this systematic review.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>We found 1454 citations using the initial search strategy. Further screening narrowed the results to 74 articles. Five trials met our inclusion criteria for analysis. One of these studies was a multicenter trial in Canada and the United States (<LINK REF="STD-Forsyth-2003" TYPE="STUDY">Forsyth 2003</LINK>). The other trials were from Italy (<LINK REF="STD-Franceschetti-1990" TYPE="STUDY">Franceschetti 1990</LINK>), Australia (<LINK REF="STD-North-1983" TYPE="STUDY">North 1983</LINK>), Taiwan (<LINK REF="STD-Lee-1989" TYPE="STUDY">Lee 1989</LINK>), and the United States (<LINK REF="STD-Glantz-1996" TYPE="STUDY">Glantz 1996</LINK>). The treatment sequence of all trials had a classic parallel design. In three trials (<LINK REF="STD-Franceschetti-1990" TYPE="STUDY">Franceschetti 1990</LINK>; <LINK REF="STD-Lee-1989" TYPE="STUDY">Lee 1989</LINK>; <LINK REF="STD-North-1983" TYPE="STUDY">North 1983</LINK>) the participants with brain tumors formed one of several subgroups that included several non-neoplastic conditions. The eligibility criteria were uniform for all studies, overall. The main goal of two trials was to investigate whether antiepileptic drugs could prevent seizures in the early or late postoperative periods (<LINK REF="STD-Franceschetti-1990" TYPE="STUDY">Franceschetti 1990</LINK>; <LINK REF="STD-Lee-1989" TYPE="STUDY">Lee 1989</LINK>) and one study followed participants for up to 12 months after craniotomy (<LINK REF="STD-North-1983" TYPE="STUDY">North 1983</LINK>). The remaining two studies assessed the value of seizure prevention without surgery as a potential confounding variable (<LINK REF="STD-Forsyth-2003" TYPE="STUDY">Forsyth 2003</LINK>; <LINK REF="STD-Glantz-1996" TYPE="STUDY">Glantz 1996</LINK>). All the included trials enrolled participants with gliomas and brain metastases; three studies included participants with meningiomas (<LINK REF="STD-Franceschetti-1990" TYPE="STUDY">Franceschetti 1990</LINK>; <LINK REF="STD-Lee-1989" TYPE="STUDY">Lee 1989</LINK>; <LINK REF="STD-North-1983" TYPE="STUDY">North 1983</LINK>) and three trials included patients with sellar tumors (<LINK REF="STD-Franceschetti-1990" TYPE="STUDY">Franceschetti 1990</LINK>; <LINK REF="STD-Lee-1989" TYPE="STUDY">Lee 1989</LINK>; <LINK REF="STD-North-1983" TYPE="STUDY">North 1983</LINK>); one study included sellar tumors without specifying type (<LINK REF="STD-North-1983" TYPE="STUDY">North 1983</LINK>). The design of two trials included an estimate of how many participants were necessary to detect a difference in favor of the treatment intervention (<LINK REF="STD-Glantz-1996" TYPE="STUDY">Glantz 1996</LINK>; <LINK REF="STD-Forsyth-2003" TYPE="STUDY">Forsyth 2003</LINK>). These two trials specified the subtype of glioma (glioblastoma, anaplastic astrocytoma, etc). The antiepileptic drugs tested were phenytoin alone (<LINK REF="STD-Lee-1989" TYPE="STUDY">Lee 1989</LINK>; <LINK REF="STD-North-1983" TYPE="STUDY">North 1983</LINK>) phenobarbital or phenytoin (<LINK REF="STD-Forsyth-2003" TYPE="STUDY">Forsyth 2003</LINK>; <LINK REF="STD-Franceschetti-1990" TYPE="STUDY">Franceschetti 1990</LINK>), and divalproex sodium (<LINK REF="STD-Glantz-1996" TYPE="STUDY">Glantz 1996</LINK>). All trials planned and described drug-level monitoring.</P>
<P>We did not identify any prospective, controlled studies (randomized or nonrandomized) of seizure prophylaxis in adults or children with brain tumors using newer antiepileptic drugs.</P>
<P>We excluded the following studies and study reports.<BR/>
</P>
<UL>
<LI>
<B>
<I>Clinical trials with random allocation</I>
</B>. One placebo-controlled trial with random allocation published overall results for the treatment and control groups but did not include data for the subsets of participants with brain tumors (<LINK REF="STD-Foy-1992" TYPE="STUDY">Foy 1992</LINK>). Two trials were later published with the inclusion of more patients so we excluded the earlier articles (<LINK REF="STD-North-1980" TYPE="STUDY">North 1980</LINK>; <LINK REF="STD-Franceschetti-1988" TYPE="STUDY">Franceschetti 1988</LINK>). One trial appeared as an abstract and did not contain data on participants with brain tumors (<LINK REF="STD-Holland-1995" TYPE="STUDY">Holland 1995</LINK>). Two trials evaluated seizure prevention using diazepam after the injection of contrast media in participants with brain metastases or with gliomas (<LINK REF="STD-Pagani-1983" TYPE="STUDY">Pagani 1983</LINK>; <LINK REF="STD-Pagani-1984" TYPE="STUDY">Pagani 1984</LINK>). Five other controlled trials with random allocation did not meet inclusion criteria for this review because they compared two antiepileptics: zonisamide with phenobarbital (<LINK REF="STD-Nakamura-1999" TYPE="STUDY">Nakamura 1999</LINK>); phenytoin with valproic acid (<LINK REF="STD-Beenen-1999" TYPE="STUDY">Beenen 1999</LINK>; <LINK REF="STD-Zhang-2000" TYPE="STUDY">Zhang 2000</LINK>); phenytoin as add-on to phenobarbital or carbamazepine with either of these drugs alone (<LINK REF="STD-De-Santis-2002" TYPE="STUDY">De Santis 2002</LINK>); and different doses of phenytoin (<LINK REF="STD-Levati-1996" TYPE="STUDY">Levati 1996</LINK>). </LI>
<LI>
<B>
<I>Retrospective studies</I>
</B>. We found nine studies: two were abstracts that have not been fully published (<LINK REF="STD-Dent-1996" TYPE="STUDY">Dent 1996</LINK>; <LINK REF="STD-Hung-1991" TYPE="STUDY">Hung 1991</LINK>); four articles dealt with seizure prevention in patients with gliomas (<LINK REF="STD-Boarini-1985" TYPE="STUDY">Boarini 1985</LINK>; <LINK REF="STD-Mahaley-1981" TYPE="STUDY">Mahaley 1981</LINK>; <LINK REF="STD-Mauro-2007" TYPE="STUDY">Mauro 2007</LINK>; <LINK REF="STD-Moots-1995" TYPE="STUDY">Moots 1995</LINK>); and three studies were on patients with brain metastases (<LINK REF="STD-Byrne-1983" TYPE="STUDY">Byrne 1983</LINK>; <LINK REF="STD-Cohen-1988" TYPE="STUDY">Cohen 1988</LINK>; <LINK REF="STD-Hagen-1990" TYPE="STUDY">Hagen 1990</LINK>). None of these were clinical trials but rather reviews of retrospective data from clinical charts.</LI>
<LI>
<B>
<I>Prospective trials</I>
</B>. One prospective study enrolled participants with meningiomas but there was no control group (<LINK REF="STD-Tsuji-1993" TYPE="STUDY">Tsuji 1993</LINK>).</LI>
</UL>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>
<B>Risk of bias in included studies</B> <BR/>We rated and summarized study validity using a simple but effective approach outlined in the Cochrane Handbook for Systematic Reviews of Interventions (<LINK REF="REF-Higgins-2006" TYPE="REFERENCE">Higgins 2006</LINK>) (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). Three of the included trials were very vulnerable to bias: in one, the sequence generation and allocation concealment were unclear (<LINK REF="STD-North-1983" TYPE="STUDY">North 1983</LINK>); in another, the authors described the sequence generation but not allocation concealment (<LINK REF="STD-Lee-1989" TYPE="STUDY">Lee 1989</LINK>); in the remaining trial the sequence generation was unclear and there was no allocation concealment (<LINK REF="STD-Franceschetti-1990" TYPE="STUDY">Franceschetti 1990</LINK>). One trial described sequence generation, allocation concealment, did not report results selectively, was free from other bias, included information on adverse events and withdrawals from the study, and had the lowest risk of bias (<LINK REF="STD-Glantz-1996" TYPE="STUDY">Glantz 1996</LINK>). The fifth trial had a moderate risk of bias because it did not include a placebo intervention (<LINK REF="STD-Forsyth-2003" TYPE="STUDY">Forsyth 2003</LINK>) (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<UL>
<LI>
<B>
<I>Effectiveness to prevent seizures</I>
</B>. For this outcome there were 404 participants: 210 allocated to the group treated with antiepileptic drugs, and 194 allocated to the control group. Prophylaxis with the antiepileptic drugs phenytoin, phenobarbital, or divalproex sodium was no better than placebo or observation (RR 0.94, 95% CI 0.55 to 1.61; P = 0.82). The trials were ranked by weight in a forest plot. One trial was the least precise and contributed little to the meta-analysis because participants were followed for 72 hours after surgery and there were no seizures in the treatment group (<LINK REF="STD-Lee-1989" TYPE="STUDY">Lee 1989</LINK>). Therefore, a sensitivity analysis without this trial was unnecessary. The model was reasonably homogeneous (I<SUP>2</SUP> = 38.5%) and the funnel plot did not suggest publication bias (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</LI>
<LI>
<B>
<I>Adverse events</I>
</B>. One study did not report adverse events (<LINK REF="STD-Lee-1989" TYPE="STUDY">Lee 1989</LINK>) and another reported them but gave only overall results (<LINK REF="STD-North-1983" TYPE="STUDY">North 1983</LINK>). Franchescetti and collaborators reported that three patients in the group allocated to phenytoin and one participant in the group allocated to phenobarbital had neurological adverse effects in the first postoperative week without further detail (<LINK REF="STD-Franceschetti-1990" TYPE="STUDY">Franceschetti 1990</LINK>). Two trials detailed the adverse events. In one trial 13 of 46 participants taking antiepileptic drugs had adverse events: nausea (4), rash (3), sore gums (1), myelosuppression (1), increased levels of lactate dehydrogenase (1), vertigo and blurred vision (1), tremor (1), and gait ataxia (1) (<LINK REF="STD-Forsyth-2003" TYPE="STUDY">Forsyth 2003</LINK>). Glantz and collaborators reported three patients who developed skin rash (two receiving divalproex sodium, one allocated to placebo) (<LINK REF="STD-Glantz-1996" TYPE="STUDY">Glantz 1996</LINK>). Overall, there were 237 participants with data for this outcome: 124 allocated to the treatment group, and 113 to the control group. The participants who received antiepileptics were more likely to have adverse effects (19 events in the treatment group (15% of participants), and one in the control group (0.9%) (RR 6.10, 95% CI 1.10 to 34.63; P = 0.04). The number of participants taking antiepileptic drugs for one to experience an adverse effect (NNH) was three (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>). The model was homogeneous with a symmetric funnel plot (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</LI>
</UL>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>In these five clinical trials with random allocation phenobarbital, phenytoin, and divalproex sodium did not prevent seizures in people with brain tumors who had been seizure free before participation in the study. This conclusion is not new but we wished to perform a Cochrane review to address our reservations about how others had interpreted review results to formulate recommendations that influence health policies and medical decisions. A pioneer meta-analysis that addressed the merit of seizure prophylaxis for supratentorial craniotomies found that "no empirical data supporting the attitude of using AEDs prophylactically with supratentorial intracranial surgery, have been presented on a scientific basis" (<LINK REF="REF-Kuijlen-1996" TYPE="REFERENCE">Kuijlen 1996</LINK>). The scope of that meta-analysis was more global and its conclusions did not apply to people with brain tumors.</P>
<P>At a meeting of the American Society of Clinical Oncology in 1998, an abstract (<LINK REF="REF-Glantz-1998" TYPE="REFERENCE">Glantz 1998</LINK>) presented the results of a meta-analysis that later evolved into the practice parameters endorsed by the American Academy of Neurology (<LINK REF="REF-AAN-2000" TYPE="REFERENCE">AAN 2000</LINK>). This meta-analysis set out to answer a more specific question about the efficacy of antiepileptic drugs to prevent seizures in people with brain tumors. The focus was no longer on postoperative seizures. The AAN review concluded that seizure prophylaxis was not effective in patients with brain tumors. Therefore, the panel did not recommend its routine use and recommended that antiepileptic drugs be tapered off after the first postoperative week.</P>
<P>There are four pitfalls in the AAN review that weaken the strength of its conclusions. First, the reviewers misclassified eight studies as level II evidence (evidence provided by one or more well-designed observational studies with concurrent controls) instead of level III evidence (evidence provided by studies with nonrandomized historical controls), since all those studies were retrospective chart reviews and not clinical trials. <BR/>Secondly, there was no exploration of clinical or statistical heterogeneity despite acknowledging the importance of heterogeneity as background noise in the interpretation of meta-analytic results. Randomized, controlled clinical trials are less susceptible, but not immune, to multiple sources of bias and can suffer from heterogeneity. <BR/>Third, the adverse event rate quoted in the AAN review (23.8%) is the pooled result from three randomized trials (<LINK REF="STD-Forsyth-2003" TYPE="STUDY">Forsyth 2003</LINK>; <LINK REF="STD-Franceschetti-1990" TYPE="STUDY">Franceschetti 1990</LINK>; <LINK REF="STD-Glantz-1996" TYPE="STUDY">Glantz 1996</LINK>), and four retrospective studies with historical controls (<LINK REF="STD-Hagen-1990" TYPE="STUDY">Hagen 1990</LINK>; <LINK REF="STD-Hung-1991" TYPE="STUDY">Hung 1991</LINK>; <LINK REF="STD-Mahaley-1981" TYPE="STUDY">Mahaley 1981</LINK>; <LINK REF="STD-Moots-1995" TYPE="STUDY">Moots 1995</LINK>). This indicates a selective bias in the reporting of outcomes. Finally, four of the main authors of the AAN review were the principal investigators or coauthors of two clinical trials included in the meta-analysis. The clinical trials included in all these systematic reviews are of good quality but we have concerns about their extracting data from subgroups (brain tumors, aneurysms, arteriovenous malformations) and analyzing data from subsets of subgroups (brain metastases, sellar tumors, gliomas) with even fewer participants. Therefore, the probability of detecting a difference is zero. This flaw is applicable to another review (<LINK REF="REF-Sirven-2004" TYPE="REFERENCE">Sirven 2004</LINK>) and we chose not to analyze subgroup data because of the imprecision of these meta-analysis results.</P>
<P>The second group published their meta-analysis with similar results to those of the AAN meta-analysis (<LINK REF="REF-Sirven-2004" TYPE="REFERENCE">Sirven 2004</LINK>) when our review was under development. These reviewers pointed out some of the methodological flaws of the earlier review, such as the presence of clinical heterogeneity and the confounding effect of surgery, yet they analyzed subsets of subgroups by examining three tumor types separately. The wide 95% confidence intervals attest to the large uncertainty and imprecision of these results. Based on these subset analyses, one conclusion of the review was that antiepileptic drugs were not effective in preventing seizures in people with gliomas, metastases, or meningiomas. </P>
<P>The best data we have is from a collection of different brain tumors with different seizure risks, each subgroup with few participants. Therefore, the strength of evidence showing that antiepileptic drugs are ineffective for seizure prophylaxis is not as solid as stated in previous reviews on this topic and is largely based on two trials, only one of which had enough statistical power (<LINK REF="STD-Glantz-1996" TYPE="STUDY">Glantz 1996</LINK>). Evidence of this nature is inconclusive and hence we prefer to say that the best evidence available at present is neither in favor nor against seizure prophylaxis in brain tumors.</P>
<P>However, it is unlikely from these results that there is a clinically important effect of phenytoin, phenobarbital, and divalproex sodium in preventing seizures in the absence of careful drug-level monitoring. Therefore, it is important to test the efficacy of newer antiepileptic drugs in this setting, beginning with phase II studies. Levetiracetam could be a promising candidate because it has an intravenous formulation and can be used preoperatively and in the immediate postoperative period. The design of these trials should include random allocation maintained throughout the trial, control with the use of placebo, double blinding, and follow up for one to three months to avoid the problem of high mortality rates present in at least one trial (<LINK REF="STD-Forsyth-2003" TYPE="STUDY">Forsyth 2003</LINK>) and no outcomes after a very short follow-up (<LINK REF="STD-Lee-1989" TYPE="STUDY">Lee 1989</LINK>).</P>
<P>
<B>Adverse events</B>
<BR/>As for the seizure outcome, an analysis of adverse effects is difficult and incomplete because some clinical trials did not routinely report adverse events. In our review we tried to compare the adverse event rate between treatment with antiepileptic drugs and control interventions. The risk of adverse effects was significantly higher in people taking antiepileptic drugs but not as high as presented in the AAN review, in which the data from retrospective studies could have inflated the estimate. However, we recognize that older antiepileptic drugs may have a higher rate of adverse events. Therefore, the risk-to-benefit analysis of seizure prophylaxis can improve by using newer antiepileptic drugs. We do not underestimate the toxicity of the older generations of antiepileptic drugs and decisions about seizure prophylaxis need to weigh up the side-effect profile of these drugs.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>The evidence for seizure prophylaxis with phenobarbital, phenytoin, and divalproex sodium in people with brain tumors is inconclusive, at best. The clinical heterogeneity between and within trials limits any claim of effectiveness or ineffectiveness. Therefore, there are no data supporting the use of prophylactic antiepileptics and the risk of adverse events lessens their overall potential benefit. Use of these antiepileptic drugs is associated with a higher risk of adverse events than in a control group, which is a major factor to consider when deciding to start seizure prophylaxis.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>There is a need for trials using adaptive randomization methods that will allow us to test different newer antiepileptics. The active participation of neurosurgeons as investigators in these trials may enhance the impact of these trials in changing clinical management paradigms and longstanding dogmas.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>Vivien Liu, RN, Research Nurse Supervisor for clinical trials in the Neuro-Oncology Department, and Weiming She, MD, Department of Neurosurgery, The University of Texas - MD Anderson Cancer Center translated one trial published in Chinese (<LINK REF="STD-Zhang-2000" TYPE="STUDY">Zhang 2000</LINK>).</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Ivo W Tremont-Lukats: conception and planning of the protocol, literature search, data collection and analyis, and manuscript writing.<BR/>Bernardo Ratilal: literature search, data collection and analysis, manuscript writing.<BR/>Terri Armstrong: literature search, data collection, analysis and manuscript writing.<BR/>Mark R Gilbert: typescript proofreading, editing, and advice on methodology.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Forsyth-2003" NAME="Forsyth 2003" YEAR="2003">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Forsyth PA, Weaver S, Fulton D, Brasher PM, Sutherland G, Stewart D, et al</AU>
<TI>Prophylactic anticonvulsants in patients with brain tumour</TI>
<SO>The Canadian Journal of Neurological Sciences. Le Journal Canadien des Sciences Neurologiques</SO>
<YR>2003</YR>
<VL>30</VL>
<NO>2</NO>
<PG>106-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Franceschetti-1990" NAME="Franceschetti 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Franceschetti S, Binelli S, Casazza M, Lodrini S, Panzica F, Pluchino F, et al</AU>
<TI>Influence of surgery and antiepileptic drugs on seizures symptomatic of cerebral tumours</TI>
<SO>Acta Neurochirurgica</SO>
<YR>1990</YR>
<VL>103</VL>
<NO>1-2</NO>
<PG>47-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Glantz-1996" NAME="Glantz 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Glantz MJ, Cole BF, Friedberg MH, Lathi E, Choy H, Furie K, et al</AU>
<TI>A randomized, blinded, placebo-controlled trial of divalproex sodium prophylaxis in adults with newly diagnosed brain tumors</TI>
<SO>Neurology</SO>
<YR>1996</YR>
<VL>46</VL>
<NO>4</NO>
<PG>985-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-1989" NAME="Lee 1989" YEAR="1989">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lee ST, Lui TN, Chang CN, Cheng WC, Wang DJ, Heimburger RF, Lin CG</AU>
<TI>Prophylactic anticonvulsants for prevention of immediate and early postcraniotomy seizures</TI>
<SO>Surgical Neurology</SO>
<YR>1989</YR>
<VL>31</VL>
<NO>5</NO>
<PG>361-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-North-1983" NAME="North 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>North JB, Penhall RK, Hanieh A, Frewin DB, Taylor WB</AU>
<TI>Phenytoin and postoperative epilepsy. A double-blind study</TI>
<SO>Journal of Neurosurgery</SO>
<YR>1983</YR>
<VL>58</VL>
<NO>5</NO>
<PG>672-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Avanzini-1982" NAME="Avanzini 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Avanzini G, Boroni S, Franceschetti S, Solero CL, Spreafico R</AU>
<TI>Pharmacologic prophylaxis of epileptic seizures occurring after surgery for intracranial tumors</TI>
<TO>Crisi post-operatorie e profilassi farmacologica in soggetti affetti da neoplasie cerebrali</TO>
<SO>Bolletino Lega Italiana contro L'Epilessia</SO>
<YR>1982</YR>
<VL>39</VL>
<PG>53-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beenen-1999" NAME="Beenen 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beenen LF, Lindeboom J, Kasteleijn-Nolst Trenite DG, Heimans JJ, Snoek FJ, et al</AU>
<TI>Comparative double blind clinical trial of phenytoin and sodium valproate as anticonvulsant prophylaxis after craniotomy: efficacy, tolerability, and cognitive effects</TI>
<SO>Journal of Neurology, Neurosurgery, and Psychiatry</SO>
<YR>1999</YR>
<VL>67</VL>
<NO>4</NO>
<PG>474-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boarini-1985" NAME="Boarini 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boarini DJ, Beck DW, VanGilder JC</AU>
<TI>Postoperative prophylactic anticonvulsant therapy in cerebral gliomas</TI>
<SO>Neurosurgery</SO>
<YR>1985</YR>
<VL>16</VL>
<NO>3</NO>
<PG>290-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Byrne-1983" NAME="Byrne 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Byrne TN, Cascino TL, Posner JB</AU>
<TI>Brain metastasis from melanoma</TI>
<SO>Journal of Neuro-oncology</SO>
<YR>1983</YR>
<VL>1</VL>
<NO>4</NO>
<PG>313-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cohen-1988" NAME="Cohen 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cohen N, Strauss G, Lew R, Silver D, Recht L</AU>
<TI>Should prophylactic anticonvulsants be administered to patients with newly-diagnosed cerebral metastases? A retrospective analysis</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1988</YR>
<VL>6</VL>
<NO>10</NO>
<PG>1621-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Santis-2002" NAME="De Santis 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Santis A, Villani R, Sinisi M, Stocchetti N, Perucca E</AU>
<TI>Add-on phenytoin fails to prevent early seizures after surgery for supratentorial brain tumors: A randomized controlled study</TI>
<SO>Epilepsia</SO>
<YR>2002</YR>
<VL>43</VL>
<NO>2</NO>
<PG>175-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Dent-1996" NAME="Dent 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dent S, Bociek G</AU>
<TI>Prophylactic anticonvulsants for cancer patients with newly diagnosed brain metastases</TI>
<SO>American Society of Clinical Oncology Proceedings</SO>
<YR>1996</YR>
<VL>15</VL>
<PG>529</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Foy-1992" NAME="Foy 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Foy PM, Chadwick DW, Rajgopalan N, Johnson AL, Shaw MD</AU>
<TI>Do prophylactic anticonvulsant drugs alter the pattern of seizures after craniotomy?</TI>
<SO>Journal of Neurology, Neurosurgery, and Psychiatry</SO>
<YR>1992</YR>
<VL>55</VL>
<NO>9</NO>
<PG>753-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Franceschetti-1988" NAME="Franceschetti 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Franceschetti S, Binelli S, Casazza M, Croci D, Lodrini S, Panzica F, et al</AU>
<TI>Postoperative seizures in patients operated on supratentorial neoplasms: A prospective study</TI>
<TO>Crisi postoperatorie in pazienti operati per neoplasie sopratentoriali: studio prospettico</TO>
<SO>Bolletino della Lega Italiana contro L'Epilessia</SO>
<YR>1988</YR>
<VL>62-63</VL>
<PG>413-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hagen-1990" NAME="Hagen 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hagen NA, Cirrincione C, Thaler HT, DeAngelis LM</AU>
<TI>The role of radiation therapy following resection of single brain metastasis from melanoma</TI>
<SO>Neurology</SO>
<YR>1990</YR>
<VL>40</VL>
<NO>1</NO>
<PG>158-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Holland-1995" NAME="Holland 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holland JP, Stapleton SR, Moore AJ, Marsh HT, Uttley D, Bell BA</AU>
<TI>A randomised double blind study of sodium valproate for the prevention of seizures in neurosurgical patients</TI>
<SO>Journal of Neurology, Neurosurgery, and Psychiatry</SO>
<YR>1995</YR>
<VL>58</VL>
<PG>116</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Hung-1991" NAME="Hung 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hung S, Hilsenbeck S, Feun L</AU>
<TI>Seizure prophylaxis with phenytoin in patients with brain metastases</TI>
<SO>American Society of Clinical Oncology Proceedings</SO>
<YR>1991</YR>
<VL>10</VL>
<PG>327</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levati-1996" NAME="Levati 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levati A, Savoia G, Zoppi F, Boselli L, Tommasino C</AU>
<TI>Peri-operative prophylaxis with phenytoin: dosage and therapeutic plasma levels. Acta neurochirurgica</TI>
<SO>Acta Neurochirurgica</SO>
<YR>1996</YR>
<VL>138</VL>
<NO>3</NO>
<PG>274-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mahaley-1981" NAME="Mahaley 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mahaley MS Jr, Dudka L</AU>
<TI>The role of anticonvulsant medications in the management of patients with anaplastic gliomas</TI>
<SO>Surgical Neurology</SO>
<YR>1981</YR>
<VL>16</VL>
<NO>6</NO>
<PG>399-401</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mauro-2007" NAME="Mauro 2007" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mauro AM, Bomprezzi C, Morresi S, Provinciali L, Formica F, Iacoangeli M, Scerrati M</AU>
<TI>Prevention of early postoperative seizures in patients with primary brain tumors: preliminary experience with oxcarbazepine</TI>
<SO>Journal of Neuro-oncology</SO>
<YR>2007</YR>
<VL>81</VL>
<NO>3</NO>
<PG>279-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moots-1995" NAME="Moots 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moots PL, Maciunas RJ, Eisert DR, Parker RA, Laporte K, Abou-Khalil B</AU>
<TI>The course of seizure disorders in patients with malignant gliomas</TI>
<SO>Archives of Neurology</SO>
<YR>1995</YR>
<VL>52</VL>
<NO>7</NO>
<PG>717-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nakamura-1999" NAME="Nakamura 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nakamura N, Ishijima B, Mayanagi Y, Manaka S</AU>
<TI>A randomized controlled trial of zonisamide in postoperative epilepsy: A report of the Cooperative Group Study</TI>
<SO>Japanese Journal of Neurosurgery</SO>
<YR>1999</YR>
<VL>8</VL>
<NO>10</NO>
<PG>647-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-North-1980" NAME="North 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>North JB, Penhall RK, Hanieh A, Hann CS, Challen RG, Frewin DB</AU>
<TI>Postoperative epilepsy: a double-blind trial of phenytoin after craniotomy</TI>
<SO>Lancet</SO>
<YR>1980</YR>
<VL>1</VL>
<NO>8165</NO>
<PG>384-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pagani-1983" NAME="Pagani 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pagani JJ, Hayman LA, Bigelow RH, Libshitz HI, Lepke RA, Wallace S</AU>
<TI>Diazepam prophylaxis of contrast media-induced seizures during computed tomography of patients with brain metastases</TI>
<SO>American Journal of Roentgenology</SO>
<YR>1983</YR>
<VL>140</VL>
<NO>4</NO>
<PG>787-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pagani-1984" NAME="Pagani 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pagani JJ, Hayman LA, Bigelow RH, Libshitz HI, Lepke RA</AU>
<TI>Prophylactic diazepam in prevention of contrast media-associated seizures in glioma patients undergoing cerebral computed tomography</TI>
<SO>Cancer</SO>
<YR>1984</YR>
<VL>54</VL>
<NO>10</NO>
<PG>2200-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tsuji-1993" NAME="Tsuji 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tsuji M, Shinomiya S, Inoue R, Sato K</AU>
<TI>Prospective study of postoperative seizure in intracranial meningioma</TI>
<SO>The Japanese Journal of Psychiatry and Neurology</SO>
<YR>1993</YR>
<VL>47</VL>
<NO>2</NO>
<PG>331-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2000" NAME="Zhang 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang Y, Zhou LF, Du GH, Gao L, Xu B, Xu J, Gu YX</AU>
<TI>Phenytoin or sodium valproate for prophylaxis of postoperative epilepsy: a randomized comparison</TI>
<SO>Chinese Journal of Nervous and Mental Diseases</SO>
<YR>2000</YR>
<VL>26</VL>
<NO>4</NO>
<PG>231-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-AAN-2000" NAME="AAN 2000" TYPE="JOURNAL_ARTICLE">
<AU>Glantz MJ, Cole BF, Forsyth PA, Recht LD, Wen PY, Chamberlain MC, et al</AU>
<TI>Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology</TI>
<SO>Neurology</SO>
<YR>2000</YR>
<VL>54</VL>
<NO>10</NO>
<PG>1886-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Agbi-1993" NAME="Agbi 1993" TYPE="JOURNAL_ARTICLE">
<AU>Agbi CB, Bernstein M</AU>
<TI>Seizure prophylaxis for brain tumour patients. Brief review and guide for family physicians</TI>
<SO>Canadian Family Physician Medecin de Famille Canadien</SO>
<YR>1993</YR>
<VL>39</VL>
<PG>1153-6, 1159-60, 1163-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Batchelor-2006" NAME="Batchelor 2006" TYPE="JOURNAL_ARTICLE">
<AU>Batchelor TT, Byrne TN</AU>
<TI>Supportive care of brain tumor patients</TI>
<SO>Hematology/Oncology Clinics of North America</SO>
<YR>2006</YR>
<VL>20</VL>
<NO>6</NO>
<PG>1337-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brouwers-2003" NAME="Brouwers 2003" TYPE="JOURNAL_ARTICLE">
<AU>Brouwers MC, Chambers A, Perry J, The Neuro-oncology Disease Site Group</AU>
<TI>Can surveying practitioners about their practices help identify priority clinical practice guideline topics?</TI>
<SO>BMC Health Services Research</SO>
<YR>2003</YR>
<VL>3</VL>
<NO>1</NO>
<PG>23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cascino-2004" NAME="Cascino 2004" TYPE="JOURNAL_ARTICLE">
<AU>Cascino GD</AU>
<TI>"Antiepileptic" not "antiepileptogenic" drug therapy: ineffective prophylaxis of seizures</TI>
<SO>Mayo Clinic Proceedings</SO>
<YR>2004</YR>
<VL>79</VL>
<NO>12</NO>
<PG>1487-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deutschman-1985" NAME="Deutschman 1985" TYPE="JOURNAL_ARTICLE">
<AU>Deutschman CS, Haines SJ</AU>
<TI>Anticonvulsant prophylaxis in neurological surgery</TI>
<SO>Neurosurgery</SO>
<YR>1985</YR>
<VL>17</VL>
<NO>3</NO>
<PG>510-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Glantz-1997" NAME="Glantz 1997" TYPE="BOOK_SECTION">
<AU>Glantz M, Recht LD</AU>
<TI>Epilepsy in the cancer patient</TI>
<SO>Handbook of Neurology</SO>
<YR>1997</YR>
<VL>25(69): Neuro-oncology, Part III</VL>
<PG>9-18</PG>
<ED>Vinken PJ, Bruyn GW</ED>
<PB>Elsevier</PB>
<CY>Amsterdam</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Glantz-1998" NAME="Glantz 1998" TYPE="JOURNAL_ARTICLE">
<AU>Glantz MJ, Cole BF, Forsyth PA, Recht L</AU>
<TI>Meta-analysis of anticonvulsant prophylaxis (ACP) in seizure-naive patients (pts) with brain tumors</TI>
<SO>American Society of Clinical Oncology Proceedings</SO>
<YR>1998</YR>
<VL>17</VL>
<PG>388a</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2006" NAME="Higgins 2006" TYPE="COCHRANE_REVIEW">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Aproaches to summarising the validity of studies. Section 6.7. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>3</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hildebrand-2005" NAME="Hildebrand 2005" TYPE="JOURNAL_ARTICLE">
<AU>Hildebrand J, Lecaille C, Perennes J, Delattre JY</AU>
<TI>Epileptic seizures during follow-up of patients treated for primary brain tumors</TI>
<SO>Neurology</SO>
<YR>2005</YR>
<VL>65</VL>
<PG>212-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ketz-1974" NAME="Ketz 1974" TYPE="BOOK_SECTION">
<AU>Ketz E</AU>
<TI>Brain tumours and epilepsy</TI>
<SO>Handbook of Clinical Neurology</SO>
<YR>1974</YR>
<VL>16</VL>
<PG>254-69</PG>
<ED>Vinken PJ, Bruyn GW</ED>
<PB>North-Holland Publishing Company</PB>
<CY>Amsterdam</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kuijlen-1996" NAME="Kuijlen 1996" TYPE="JOURNAL_ARTICLE">
<AU>Kuijlen JM, Teernstra OP, Kessels AG, Herpers MJ, Beuls EA</AU>
<TI>Effectiveness of antiepileptic prophylaxis used with supratentorial craniotomies: a meta-analysis</TI>
<SO>Seizure</SO>
<YR>1996</YR>
<VL>5</VL>
<NO>4</NO>
<PG>291-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kvam-1983" NAME="Kvam 1983" TYPE="JOURNAL_ARTICLE">
<AU>Kvam DA, Loftus CM, Copeland B, Quest DO</AU>
<TI>Seizures during the immediate post-operative period</TI>
<SO>Neurosurgery</SO>
<YR>1983</YR>
<VL>12</VL>
<NO>1</NO>
<PG>14-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lackner-1991" NAME="Lackner 1991" TYPE="JOURNAL_ARTICLE">
<AU>Lackner TE</AU>
<TI>Interaction of dexamethasone with phenytoin</TI>
<SO>Pharmacotherapy</SO>
<YR>1991</YR>
<VL>11</VL>
<NO>4</NO>
<PG>344-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NCC-2006" NAME="NCC 2006" TYPE="COMPUTER_PROGRAM">
<TI>RevMan Analyses [computer program]. Version 1.0 for Windows. In: Review Manager (RevMan) 4.2.10</TI>
<YR>2006</YR>
<PB>The Cochrane Collaboration</PB>
<CY>Oxford, England</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Patsalos-2002" NAME="Patsalos 2002" TYPE="JOURNAL_ARTICLE">
<AU>Patsalos PN, Fröscher W, Pisani F, van Rijn CM</AU>
<TI>The importance of drug interactions in epilepsy therapy</TI>
<SO>Epilepsia</SO>
<YR>2002</YR>
<VL>43</VL>
<NO>4</NO>
<PG>365-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ruegg-2002" NAME="Ruegg 2002" TYPE="JOURNAL_ARTICLE">
<AU>Ruegg S</AU>
<TI>Dexamethasone/phenytoin interactions: neurooncological concerns</TI>
<SO>Swiss Medical Weekly</SO>
<YR>2002</YR>
<VL>132</VL>
<NO>29-30</NO>
<PG>425-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Siomin-2005" NAME="Siomin 2005" TYPE="JOURNAL_ARTICLE">
<AU>Siomin V, Angelov L, Vogelbaum MA</AU>
<TI>Results of a survey of neurosurgical practice patterns regarding the prophylactic use of anti-epilepsy drugs in patients with brain tumors</TI>
<SO>Journal of Neuro-oncology</SO>
<YR>2005</YR>
<VL>74</VL>
<NO>2</NO>
<PG>211-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sirven-2004" NAME="Sirven 2004" TYPE="JOURNAL_ARTICLE">
<AU>Sirven JI, Wingerchuk DM, Drazkowski JF, Lyons MK, Zimmerman RS</AU>
<TI>Seizure prophylaxis in patients with brain tumors: a meta-analysis</TI>
<SO>Mayo Clinic Proceedings</SO>
<YR>2004</YR>
<VL>79</VL>
<NO>12</NO>
<PG>1489-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vecht-2003" NAME="Vecht 2003" TYPE="JOURNAL_ARTICLE">
<AU>Vecht CJ, Wagner GL, Wilms EB</AU>
<TI>Treating seizures in patients with brain tumors: Drug interactions between antiepileptic and chemotherapeutic agents</TI>
<SO>Seminars in Oncology</SO>
<YR>2003</YR>
<VL>30 Suppl 19</VL>
<NO>6</NO>
<PG>49-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vecht-2006" NAME="Vecht 2006" TYPE="JOURNAL_ARTICLE">
<AU>Vecht CJ, van Breemen M</AU>
<TI>Optimizing therapy of seizures in patients with brain tumors</TI>
<SO>Neurology</SO>
<YR>2006</YR>
<VL>67 Suppl 4</VL>
<NO>12</NO>
<PG>10-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wen-2002" NAME="Wen 2002" TYPE="JOURNAL_ARTICLE">
<AU>Wen PY, Marks PW</AU>
<TI>Medical management of patients with brain tumors</TI>
<SO>Current Opinions in Oncology</SO>
<YR>2002</YR>
<VL>14</VL>
<NO>3</NO>
<PG>299-307</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Forsyth-2003">
<CHAR_METHODS>
<P>Random allocation, unmasked design<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>100; 60 had brain metastases (26 in the treatment arm, 34 controls), and 40 had gliomas (20 in each arm)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment group: Phenytoin 15mg/kg oral loading in 3 divided doses, followed by 5mg/kg po qd (n=45). If intolerance, phenobarbital was used instead (n=1). The control group did not receive treatment<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>For prevention of seizures after start of therapy, phenytoin was not better than placebo in brain metastases (P = 0.6, logrank), and in gliomas (P=0.95, logrank)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Trial stopped at 100 pts because seizure and survival rates were lower than expected. The investigators had estimated the sample size for a statistical power of 80% to detect a 15% difference between groups. The trial ultimately had a power of 20% to detect a positive difference<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Franceschetti-1990">
<CHAR_METHODS>
<P>Random allocation, placebo-controlled design, unblinded <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>63 of 128 participants had never seized. They had meningioma (n=27), malignant glioma (n=23) or metastases (n=13)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group A: 65 pts with preoperative seizures (not considered in this review). Group B: 63 pts without preoperative seizures, randomized in three subgroups: no treatment (n=22); Phenobarbital 4 mg/kg/day x 5 days, then 2mg/kg/day orally (n=25); and phenytoin 10 mg/kg/d x 5 days, then 5 mg/kg/d orally once daily (n=16)<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Prophylaxis lowered early postop seizures compared with no treatment (7% vs. 18%) without reaching statistical significance. No effect in preventing late postoperative seizures. The authors recommended prevention with phenobarbital for the first postoperative wk 1, but not for later<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No trial size calculations. Unspecified adverse events in four participants in the treatment group during the first postoperative week. No mention of adverse effects in the late postoperative period and no mention of withdrawals<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Glantz-1996">
<CHAR_METHODS>
<P>Random allocation, double-blind, placebo-controlled design with calculation of sample size<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Metastatic or primary brain tumors without history of seizures</P>
<P>Placebo group: Lung cancer (n=28), non-Hodgkin lymphoma (n=2), glioblastoma (n=4), melanoma (n=1), other (n=2). Treatment group: lung cancer (n=23), breast cancer (n=4), GBM (n=5), melanoma (n=1), and other tumors (n=4)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Patients took placebo or valproic acid. Dose of valproic acid was adjusted to levels 50-100 ug/mL<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>There was no difference between valproic acid and placebo to prevent seizures (P=0.7, Fisher test)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>This trial had the highest methodological validity. It also avoided the confounding effect of surgery on seizures since participants entered the trial after 14 days of diagnosis<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lee-1989">
<CHAR_METHODS>
<P>Random allocation, double-blind, placebo-controlled design<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adult eligible patients without history of seizures, who had meningioma (n=50), glioma (n=30), metastases (n=5)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Phenytoin: 15mg/kg intravenously before wound closure, then 5-6 mg/kg/day intravenously, or placebo three times daily in the first three postoperative days<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Phenytoin was not more effective than placebo to prevent immediate and early postoperative seizures<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Study with no power to compare the subset with brain tumors<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-North-1983">
<CHAR_METHODS>
<P>Random allocation, double-blind design<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Participants with a supratentorial tumor, allocated to</P>
<P>1. Phenytoin: Meningioma (n=10), metastasis (n=6), sellar tumor (n=10), glioma (n=16)</P>
<P>2. Placebo group: meningioma (n=9), metastasis (n=7), sellar tumor (n=7), glioma (n=16)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Phenytoin 250 mg twice daily iv, then 100 mg orally three times daily x 12 months. Serum levels once a month for inpatients, bimonthly for outpatients. Doses were adjusted accordingly<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>18 seizures in group treated with phenytoin, 26 in placebo group. By time-to-event analysis, group treated with PHT had significantly fewer seizures between days 7-72 of study. The maximal protective effect was in postop week 2<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Because 65% of seizures occurred within 3 mo from surgery, authors recommended prophylaxis for 2-3 mo, starting 1 wk before surgery. Focal seizures in 7/9 pts with therapeutic levels<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Avanzini-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a clinical trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Beenen-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial with random allocation that compared two anticonvulsants (phenytoin and valproic acid)<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Boarini-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Retrospective chart review<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Byrne-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Retrospective study<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cohen-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Retrospective study<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-De-Santis-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Inclusion of participants with history of seizures<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dent-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Retrospective study with historical controls<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Foy-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome data not extractable for patients with brain tumors in the results section<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Franceschetti-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>It is a duplicate of Franceschetti 1990 with fewer patients<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hagen-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Retrospective chart review<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Holland-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>A double-blind, randomized trial using valproic acid for prevention of seizures after craniotomy or head injury, this trial has not been fully published, and no data about brain tumors are in the abstract<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hung-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Retrospective chart review<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Levati-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study with random allocation comparing three different doses of phenytoin for prevention of postoperatory seizures in participants with supratentorial brain tumors, there was no placebo or suitable control group<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mahaley-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a controlled clinical trial, but a retrospective study<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mauro-2007">
<CHAR_REASON_FOR_EXCLUSION>
<P>Retrospective study<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Moots-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>A retrospective review<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nakamura-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Double-blind trial with random allocation comparing zonisamide with phenobarbital<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-North-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>This trial was later expanded and published elsewhere, North 1983<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pagani-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Prevention of seizures induced by contrast media in patients with brain metastases<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pagani-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Prevention of seizures induced by contrast media in patients with glioma<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tsuji-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Observational study of 20 patients with meningioma who received valproic acid for seizure prevention, this study did not use a control group<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zhang-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>A controlled clinical trial with random allocation that compared phenytoin and valproic acid for the prevention of postoperatory seizures<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Forsyth-2003">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Franceschetti-1990">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Glantz-1996">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lee-1989">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-North-1983">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES>
<ADDITIONAL_TABLE ID="TBL-01" NO="1">
<TITLE>Categories of Risk of Bias and Their Meaning</TITLE>
<TABLE COLS="3" ROWS="5">
<TR>
<TH>
<P>Risk of Bias</P>
</TH>
<TH>
<P>Interpretation</P>
</TH>
<TH>
<P>Individual Criteria</P>
</TH>
</TR>
<TR>
<TD>
<P>Low<BR/>
<BR/>
<BR/>
<BR/>
<BR/>Interpretation<BR/>
<BR/>
<BR/>
<BR/>Relation to individual criteria<BR/>
<BR/>
<BR/>
<BR/>Low<BR/>
<BR/>
<BR/>
<BR/>Bias unlikely to alter results<BR/>
<BR/>
<BR/>
<BR/>All criteria met<BR/>
<BR/>
<BR/>
<BR/>Moderate<BR/>
<BR/>
<BR/>
<BR/>Bias that raises some doubt about results<BR/>
<BR/>
<BR/>
<BR/>One or more criteria partly met<BR/>
<BR/>
<BR/>
<BR/>High<BR/>
<BR/>
<BR/>
<BR/>Bias that seriously weakens confidence in the results<BR/>
<BR/>
<BR/>
</P>
</TD>
<TD>
<P>
<BR/>Bias unlikely to alter results<BR/>
<BR/>
<BR/>
<BR/>Interpretation<BR/>
<BR/>
<BR/>
<BR/>Relation to individual criteria<BR/>
<BR/>
<BR/>
<BR/>Low<BR/>
<BR/>
<BR/>
<BR/>Bias unlikely to alter results<BR/>
<BR/>
<BR/>
<BR/>All criteria met<BR/>
<BR/>
<BR/>
<BR/>Moderate<BR/>
<BR/>
<BR/>
<BR/>Bias that raises some doubt about results<BR/>
<BR/>
<BR/>
<BR/>One or more criteria partly met<BR/>
<BR/>
<BR/>
<BR/>High<BR/>
<BR/>
<BR/>
<BR/>Bias that seriously weakens confidence in the results<BR/>
<BR/>
<BR/>
<BR/>One or more criteria not met<BR/>
<BR/>
</P>
</TD>
<TD>
<P>All criteria are met</P>
</TD>
</TR>
<TR>
<TD>
<P>Moderate</P>
</TD>
<TD>
<P>Bias that raises some questions about results</P>
</TD>
<TD>
<P>One or more criteria partly met</P>
</TD>
</TR>
<TR>
<TD>
<P>High</P>
</TD>
<TD>
<P>Bias that seriously weakens confidence in results</P>
</TD>
<TD>
<P>One or more criteria not met</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" NO="2">
<TITLE>Absolute Risk Increase (ARI) and Number Needed to Harm (NNH)</TITLE>
<TABLE COLS="3" ROWS="4">
<TR>
<TH>
<P>Trial</P>
</TH>
<TH>
<P>ARI</P>
</TH>
<TH>
<P>NNH</P>
</TH>
</TR>
<TR>
<TD>
<P>Franceschetti 1990</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>25</P>
</TD>
</TR>
<TR>
<TD>
<P>Glantz 1996</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
</TR>
<TR>
<TD>
<P>Forsyth 2003</P>
</TD>
<TD>
<P>13</P>
</TD>
<TD>
<P>6</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Prevention of seizures in participants with brain tumors</NAME>
<DICH_OUTCOME CHI2="6.503463964331686" CI_END="1.6121914192546403" CI_START="0.545174173138832" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9375100660439164" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="39" I2="38.49431592243702" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.20741660532923142" LOG_CI_START="-0.2634647264414874" LOG_EFFECT_SIZE="-0.028024060556127987" METHOD="MH" NO="1" P_CHI2="0.16457232364703756" P_Q="0.0" P_Z="0.8155355755742499" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="USER" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.14021445251698703" TOTALS="YES" TOTAL_1="210" TOTAL_2="194" WEIGHT="100.0" Z="0.23329083437661094">
<NAME>Seizure occurrence</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.5655878971224277" CI_START="0.007263215090215873" EFFECT_SIZE="0.1365079365079365" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4091868981889596" LOG_CI_START="-2.1388710946089877" LOG_EFFECT_SIZE="-0.864842098210014" ORDER="1" O_E="0.0" SE="1.4967418780599997" STUDY_ID="STD-Lee-1989" TOTAL_1="44" TOTAL_2="42" VAR="2.240236249538575" WEIGHT="3.2139488319874143"/>
<DICH_DATA CI_END="4.555132010023408" CI_START="0.6133024165359807" EFFECT_SIZE="1.6714285714285715" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.6585009675645539" LOG_CI_START="-0.2123253241007442" LOG_EFFECT_SIZE="0.22308782173190483" ORDER="2" O_E="0.0" SE="0.5115276743838613" STUDY_ID="STD-North-1983" TOTAL_1="42" TOTAL_2="39" VAR="0.2616605616605616" WEIGHT="19.0373784972236"/>
<DICH_DATA CI_END="1.200646000478221" CI_START="0.176185064768202" EFFECT_SIZE="0.45993031358885017" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.07941497850939896" LOG_CI_START="-0.7540309095656839" LOG_EFFECT_SIZE="-0.33730796552814246" ORDER="3" O_E="0.0" SE="0.48957024027898693" STUDY_ID="STD-Franceschetti-1990" TOTAL_1="41" TOTAL_2="22" VAR="0.23967902016682502" WEIGHT="20.138926577037505"/>
<DICH_DATA CI_END="2.959842967501669" CI_START="0.7049089346951116" EFFECT_SIZE="1.4444444444444444" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="9" LOG_CI_END="0.47126867046549886" LOG_CI_START="-0.15186698473047514" LOG_EFFECT_SIZE="0.15970084286751188" ORDER="4" O_E="0.0" SE="0.3660329684333557" STUDY_ID="STD-Glantz-1996" TOTAL_1="37" TOTAL_2="37" VAR="0.13398013398013398" WEIGHT="27.90225310868938"/>
<DICH_DATA CI_END="1.6845682781639633" CI_START="0.43993254409688437" EFFECT_SIZE="0.8608695652173913" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="15" LOG_CI_END="0.2264886183025341" LOG_CI_START="-0.3566139098146576" LOG_EFFECT_SIZE="-0.06506264575606176" ORDER="5" O_E="0.0" SE="0.34251731142010394" STUDY_ID="STD-Forsyth-2003" TOTAL_1="46" TOTAL_2="54" VAR="0.11731810862245648" WEIGHT="29.7074929850621"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.5673011276183146" CI_END="34.62981038985423" CI_START="1.069868372185027" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="6.0868168093733095" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="1" I2="22.09717907710343" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="1.5394501136440188" LOG_CI_START="0.02933034894676676" LOG_EFFECT_SIZE="0.7843902312953928" METHOD="MH" NO="2" P_CHI2="0.27702427898788873" P_Q="0.0" P_Z="0.041740424217103896" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.5255920204191135" TOTALS="YES" TOTAL_1="124" TOTAL_2="113" WEIGHT="100.0" Z="2.0360989096414155">
<NAME>Adverse event rate</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Fewer Adverse Events</GRAPH_LABEL_1>
<GRAPH_LABEL_2>More Adverse Events</GRAPH_LABEL_2>
<DICH_DATA CI_END="517.347183545872" CI_START="1.9296347089304537" EFFECT_SIZE="31.595744680851062" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="0" LOG_CI_END="2.7137820891168656" LOG_CI_START="0.28547510231816187" LOG_EFFECT_SIZE="1.4996285957175137" ORDER="76954" O_E="0.0" SE="1.4263995443590043" STUDY_ID="STD-Forsyth-2003" TOTAL_1="46" TOTAL_2="54" VAR="2.034615660147575" WEIGHT="30.734262153903067"/>
<DICH_DATA CI_END="87.5505652580105" CI_START="0.2774489948174049" EFFECT_SIZE="4.928571428571429" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.942258954390251" LOG_CI_START="-0.5568168442722162" LOG_EFFECT_SIZE="0.6927210550590173" ORDER="76955" O_E="0.0" SE="1.4679694947590476" STUDY_ID="STD-Franceschetti-1990" TOTAL_1="41" TOTAL_2="22" VAR="2.154934437543133" WEIGHT="29.354716417457187"/>
<DICH_DATA CI_END="21.1143884772951" CI_START="0.18944427418778026" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3245785077461414" LOG_CI_START="-0.722518516418179" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="76956" O_E="0.0" SE="1.202474925287819" STUDY_ID="STD-Glantz-1996" TOTAL_1="37" TOTAL_2="37" VAR="1.445945945945946" WEIGHT="39.91102142863975"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-01" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Risk-of-bias graph: Review authors' judgments about each risk-of-bias item presented as percentages across all included studies.<BR/>
</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAc4AAAC1CAIAAABZFohRAAARhUlEQVR42u2d70sjxx+A738SEYMi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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-02" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Funnel plot of comparison: 1 Prevention of seizures in participants with brain tumors, outcome: 1.1 Seizures.<BR/>
</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAIAAAD9V4nPAAAb80lEQVR42u3dr19U+f7Acf8EAoFA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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-03" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Funnel plot of comparison: 1 Prevention of seizures in participants with brain tumors, outcome: 1.2 Adverse Events.<BR/>
</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAIAAAD9V4nPAAAb+ElEQVR42u3dP1BUd//ocarf5M6k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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-09-25 14:53:44 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2008-09-25 14:53:44 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-09-25 14:52:51 +0100" MODIFIED_BY="[Empty name]">Search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-09-25 14:53:44 +0100" MODIFIED_BY="[Empty name]">
<P> We searched using the following free text or MeSH terms, modified to suit the different databases:</P>
<P>
<BR/>#1. Clinical trials<BR/>#2. Controlled clinical trial<BR/>#3. randomized clinical trial<BR/>#4. Random allocation<BR/>#5. Prospective study<BR/>#6. Comparative study<BR/>#7. Double blind<BR/>#8. Placebo<BR/>#9. Parallel design<BR/>#10. Crossover design<BR/>#11. #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10<BR/>#12. Brain neoplasms<BR/>#13. Brain tumors<BR/>#14. Primary brain tumors<BR/>#15. Secondary brain tumors<BR/>#16. Brain metasta*<BR/>#17. Glioma*<BR/>#18. Astrocytoma*<BR/>#19. Oligodendroglioma*<BR/>#20. Glioblastoma multiforme<BR/>#21. Glial tumors<BR/>#22. Ependymoma<BR/>#23. Meningioma<BR/>#24. #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23<BR/>#25. Seizure*<BR/>#26. Anticonvulsants<BR/>#27. Antiepileptics<BR/>#28. Phenytoin<BR/>#29. Valproic acid<BR/>#30. Sodium valproate<BR/>#31. Phenobarbi*<BR/>#32. Oxcarbazepine<BR/>#33. Lamotrigine<BR/>#34. Gabapentin<BR/>#35. Pregabalin<BR/>#36. Zonisamide<BR/>#37. Topiramate<BR/>#38. Vigabatrin<BR/>#39. Tiagabine<BR/>#40. Prophylaxis<BR/>#41. Prevention<BR/>#42. Craniotomy<BR/>#43. Epilepsy<BR/>#44. Neurosurgery<BR/>#45. Neurooncology<BR/>#46. #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43 or #44 or #45 not animal</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>